Moreover, although studies have consistently reported better efficacy of PD-1/PD-L1 inhibitors than of CT in NSCLC patients who were bTMB high, it is still unclear which kind of therapy can bTMB-low patients more benefits. Here, CD274 is linked to non-small cell lung carcinoma.